RxDoctor Payments Data

Kurt Washburn, MD

Neurology · Charlotte, NCNPI 1437108826

Payments from drug & device makers

$76,164in general payments, 2019–2025

Across 1,177 payments — averaging $64.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$32K
  • Pfizer$17K
  • Biohaven Pharmaceuticals, Inc.$4K
  • Alkermes, Inc.$3K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Sanofi$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$12,12018%
  • Speaking & faculty fees$31,08947%
  • Travel & lodging$9141%
  • Food & beverage$21,57633%
  • Education$3491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen114$31,846
Pfizer48$16,893
Biohaven Pharmaceuticals, Inc.14$4,040
Alkermes, Inc.2$3,166
Biohaven Pharmaceutical Holding Company Ltd.15$1,796
Sanofi70$1,307
AstraZeneca49$1,205
AbbVie(2 entities)65$1,116
Teva Pharmaceuticals USA, Inc.53$996
EMD Serono, Inc.45$985
Acadia Pharmaceuticals Inc80$932
Novartis55$922
Supernus Pharmaceuticals, Inc.65$819
Amgen(2 entities)31$698
TG Therapeutics, Inc.26$615
Lundbeck LLC32$602
Bristol Myers Squibb30$525
Amneal Pharmaceuticals LLC21$416
Adamas Pharmaceuticals, Inc.22$414
Genentech USA, Inc.20$409
Grifols USA, LLC21$380
Neurocrine Biosciences, Inc.16$369
Impel Pharmaceuticals Inc.20$361
UCB, Inc.13$347
MDD US Operations, LLC19$347
Lilly USA, LLC18$286
Takeda Pharmaceuticals U.S.A., Inc.12$283
Argenx US, Inc.10$276
Assertio Therapeutics, Inc.16$264
Merz Pharmaceuticals, LLC12$257
ANI Pharmaceuticals, Inc.6$250
Sunovion Pharmaceuticals Inc.13$244
Johnson & Johnson(2 entities)9$217
Acorda Therapeutics, Inc10$186
Vanda Pharmaceuticals Inc.6$158
Octapharma USA, Inc.9$158
Merz North America, Inc.9$153
Eisai Inc.6$150
Banner Life Sciences, LLC8$142
SK Life Science, Inc.7$136
Impel Pharmaceuticals LLC7$134
Alnylam Pharmaceuticals Inc.6$107
Avanir Pharmaceuticals, Inc.6$103
Kyowa Kirin, Inc.4$94
Upsher-smith Laboratories LLC6$88
GE HealthCare5$76
Collegium Pharmaceutical, Inc.4$75
Sanofi-aventis U.S. LLC2$73
Mallinckrodt Hospital Products Inc.3$71
Scilex Pharmaceuticals Inc.4$70
E.r. Squibb & Sons, L.L.C.4$64
Mallinckrodt Enterprises LLC4$60
Arbor Pharmaceuticals, Inc.3$49
Akcea Therapeutics, Inc.1$47
Bausch Health US, LLC2$45
Axsome Therapeutics, Inc.2$36
Otsuka America Pharmaceutical, Inc.1$31
GRT US Holding, Inc.2$31
Currax Pharmaceuticals LLC2$28
Otsuka Pharmaceutical Development & Commercialization, Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,164 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,524,875
Medicare patients
387
Services billed
44,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5040$501,790
CopaxoneGlatiramer Acetate70$462,517
GammakedImmune Globul G/Gly/Iga Avg 4630$431,008
Avonex Pen (4 Pack)Interferon Beta-1a39$336,998
Avonex (4 Pack)Interferon Beta-1a24$332,858
VumerityDiroximel Fumarate27$246,753
GocovriAmantadine Hcl41$137,484
IngrezzaValbenazine Tosylate13$125,567
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$124,718
Teriflunomide18$85,345
Nurtec OdtRimegepant Sulfate50$60,047
GlatopaGlatiramer Acetate26$46,792
UbrelvyUbrogepant23$40,585
Emgality PenGalcanezumab-Gnlm45$38,293
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$38,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Vumerity$31,846$579,61251 claims
Teva Pharmaceuticals USA, Inc.Copaxone$996$462,51770 claims
MDD US Operations, LLCGocovri$347$137,48441 claims
Neurocrine Biosciences, Inc.Ingrezza$369$125,56713 claims
Grifols USA, LLCGamunex-C$380$124,71812 claims
AbbVieUbrelvy, Botox$1,116$66,34943 claims
PfizerNurtec Odt$16,893$60,04750 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$283$38,22711 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$416$6,50259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →